Greenwich Awaits Its Fate

Greenwich Pharmaceuticals Inc. hopes to hear this week the final word from the FDA on the fate of Therafectin, its carbohydrate-based compound for rheumatoid arthritis.

The agency had promised to complete by today two reviews of its earlier decision to turn down marketing approval for the drug...